 |
 |
||||||||||||||
|
|
| OMML Phosphodiesterese (PDE) |
| We are engaged in the identification and development of selective PDE inhibitors for novel therapeutic applications. Our current research includes the investigation of inhibitors with the potential for use in the treatment of tropical diseases. We also provide non-clinical support for OPC PDE inhibitors that are being assessed for, or that are currently in, clinical use as therapeutic agents. |
| * OAPI, OPDC and OMML are subsidiaries of Otsuka America, Inc. (OAI), a holding company established in the U.S. in 1989. OAI is wholly owned by Otsuka Pharmaceutical Co., Ltd.
0109W-0602 |